To Understand & Research the True Meaning in Prevention and Control of Novel Coronavirus Infection
During public welfare period, this lecture has attracted 1438 visitors and learners.
中文语音&英文字幕/Chinese voice & English subtitles
LIU Changxiao is the academician of Chinese Academy of Engineering, researcher, the honorary president and tenured principal scientist of Tianjin Institute of Pharmaceutical Research, and the director of the State Key Laboratory of Drug Delivery Technology and Pharmacokinetics. As one of the pioneers and leaders of pharmacokinetic research in China, he has been engaged in pharmacological, pharmacokinetic and modern Chinese materia medica research for more than 50 years and has won many awards in China and abroad.
In view of the clinical complexity of patients with coronavirus infection and the diversity of organ and tissue injury, how to study and utilize the Chinese materia medica for clinical prevention and control of SARS-CoV-2 infection has become a challenge. After reviewing the research concerning Chinese medicinal compounds and single medicinals, and learning about the infectivity and pathogenicity of coronavirus and the resulting multiple organ dysfunction and failure, we explore the therapeutic effects of Chinese materia medica against SARS-CoV-2 infection using scientific means. Moreover, we design the framework for new drug research and development based on the possible "target", so as to expand the research strategies of new drugs.
双语版/Bilingual edition: http://jtp.cnki.net/bilingual/EBook/Detail?pykm=TCMC
中文版/Chinese edition: https://book.oversea.cnki.net/CCGBWEB/Book/Detail/OB200803001
英文版/English edition: https://book.oversea.cnki.net/CCGBWEB/Book/Detail/OB200803002
Distinguished Editor-in-Chief and editorial board members: Editor-in-Chief HUANG Luqi is the academician of Chinese Academy of Engineering and president of China Academy of Chinese Medical Sciences. The Editorial Board includes 17 professors and chief physicians from Chinese Academy of Sciences, China Academy of Chinese Medical Sciences, and first-class hospitals in China.
Strict quality control: All 70 papers are strictly selected from nearly 800 online-first papers about COVID-19 treatment with TCM by the experts organized by China Association of Chinese Medicine and National Administration of Tradition Chinese Medicine.
Authoritative resources of anti-epidemic achievements by TCM: The papers involve the latest TCM clinical practice in the first-line treatments, cover various COVID-19 cases, age groups, regions, and complications, and include different effective TCM treatments. They possess universal guiding significance to clinical treatment of COVID-19 worldwide.
电子书可在网站注册下单或联系销售人员订购/Place your order on website or contact with our sales managers